Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial

Published:2015-12 Issue:12 Volume:15 Page:1389-1397
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Bines Julie E,Danchin Margaret,Jackson Pamela,Handley Amanda,Watts Emma,Lee Katherine J,West Amanda,Cowley Daniel,Chen Mee-Yew,Barnes Graeme L,Justice Frances,Buttery Jim P,Carlin John B,Bishop Ruth F,Taylor Barry,Kirkwood Carl D

Funder

Australian National Health and Medical Research Council through a project grant

NHMRC Fellowship support

NHMRC CDA fellowship

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference36 articles.

1. Impact of rotavirus vaccination on diarrhea-related hospitalizations in Sao Paulo State, Brazil;Fernandes;Vaccine,2014

2. Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study;Bar-Zeev;Lancet Infect Dis,2015

3. Intussusception following rotavirus vaccination: an updated review of the available evidence;Rha;Expert Rev Vaccines,2014